Arab Finance: The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) has established a new subsidiary, Glow, which will specialize in producing freely priced cosmetics and cosmeceuticals, as per a statement.

This move aims to provide a wide range of high-quality products at competitive prices to meet the increasing local demand as part of Rameda’s broader strategy to expand its portfolio of freely priced products.

Leveraging Rameda’s infrastructure and robust position, Glow aims to develop various specialized brands, targeting different market segments in cosmetics, cosmeceuticals, dermatology, and other related fields.

Glow’s first wave of products is expected to be rolled out in January 2025, the statement read.

“By developing and producing high-quality, freely priced cosmetics and cosmeceuticals locally, we are expanding our product portfolio beyond the price-controlled pharmaceutical business line,” Rameda’s CEO Amr Morsy stated.

Egypt’s EDA discusses cooperation with Saudi Arabia in pharmaceutical industry Updated 12/18/2024 6:49:00 AM

Egyptian alliance to develop $200M JV for active pharmaceutical ingredients Updated 12/15/2024 8:33:00 AM

US Ambassador touts up to $40B healthcare investment opportunities in Egypt by 2025 Updated 12/15/2024 6:02:00 AM

Rameda records 22.17% YoY consolidated profit hike in 9 months Updated 11/14/2024 10:28:00 AM

Vernbro Global to open EGP 1B pharmaceuticals factory in Egypt within year Updated 10/30/2024 9:41:00 AM